MalnutritiOn Assessment With biOelectrical impedaNce Analysis in gastRic Cancer patIentS Undergoing Multimodal trEatment
Launched by MEDICAL UNIVERSITY OF LUBLIN · Feb 9, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well we can assess the nutritional status and body composition of gastric cancer patients who are receiving a combination of treatments. The goal is to see if a method called bioelectrical impedance analysis (BIA) can help doctors make better decisions about patient care by providing an objective measure of nutrition and body composition. This could be particularly important for patients experiencing malnutrition, which is common in those with gastric cancer.
To participate in this study, patients need to be at least 18 years old and have a confirmed diagnosis of gastric adenocarcinoma at stage II or III. They must also be eligible for a multimodal treatment plan decided by a team of specialists. If you join the trial, you can expect to undergo assessments to determine your nutritional status and body composition. It’s important to note that certain patients, such as those with early-stage cancer or other serious health issues, will not be eligible for this trial. The study is currently recruiting participants, and it aims to gather valuable information that could improve care for gastric cancer patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years
- • 2. Histologically confirmed gastric adenocarcinoma (or undifferentiated carcinoma)
- • 3. Stage II - III disease (cT2 cN+ and cT3-T4 cN+/-) based on the 8th edition of TNM classification
- • 4. Qualification for multimodal treatment by the decision of the multidisciplinary tumor board
- Exclusion Criteria:
- • 1. Early gastric cancer (cT1N0-3M0) scheduled for endoscopic treatment by multidisciplinary team
- • 2. Gastric stump carcinoma
- • 3. Distant metastasis
- • 4. Upfront surgery
- • 5. Other malignancies
- • 6. Contraindications to bioelectrical impedance analysis (e.g., implanted cardiac devices, metal implants or pregnancy)
About Medical University Of Lublin
The Medical University of Lublin is a distinguished academic institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university fosters a vibrant environment for medical and scientific inquiry, aiming to improve patient outcomes and contribute to the broader medical community. Its commitment to ethical research practices and patient safety ensures that all clinical trials conducted under its auspices adhere to the highest standards of scientific rigor and regulatory compliance. The Medical University of Lublin is positioned at the forefront of medical education and research in Poland, making significant contributions to the fields of medicine, pharmacy, and health sciences.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lublin, , Poland
Patients applied
Trial Officials
Zuzanna Pelc, PhD
Principal Investigator
Medical University of Lublin
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials